Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark
<h4>Introduction</h4> Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki-Ras2 Kirsten rat sarcoma (KR...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089313/?tool=EBI |
| _version_ | 1797847172668981248 |
|---|---|
| author | Tapashi Dalvi Mette Nørgaard Jon P. Fryzek Naimisha Movva Lars Pedersen Hanh Pham Hansen Jill Walker Anita Midha Norah Shire Anne-Marie Boothman James Rigas Anders Mellemgaard Torben R. Rasmussen Stephen Hamilton-Dutoit Deirdre Cronin-Fenton |
| author_facet | Tapashi Dalvi Mette Nørgaard Jon P. Fryzek Naimisha Movva Lars Pedersen Hanh Pham Hansen Jill Walker Anita Midha Norah Shire Anne-Marie Boothman James Rigas Anders Mellemgaard Torben R. Rasmussen Stephen Hamilton-Dutoit Deirdre Cronin-Fenton |
| author_sort | Tapashi Dalvi |
| collection | DOAJ |
| description | <h4>Introduction</h4> Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki-Ras2 Kirsten rat sarcoma (KRAS) mutations in NSCLC patients receiving adjuvant chemotherapy. <h4>Methods</h4> Data for stage IB/II/IIIA NSCLC patients (diagnosed: 2001–2012) were retrieved from Danish population-based registries. Tumor tissue samples were tested for PD-L1 expression using VENTANA PD-L1 (SP263) Assay in tumor cells (TC) at ≥25% cutoff and immune cells (IC) at ≥1% and ≥25% cutoffs. KRAS and EGFR mutations were tested using PCR-based assays. Follow-up began 120 days after diagnosis until death/emigration/January 1, 2015, whichever came first. Using Cox proportional hazard regression, hazard ratios (HRs) were computed for overall survival (OS) for each biomarker, adjusting for age, sex, histology, comorbidities, and tissue specimen age. <h4>Results</h4> Among 391 patients identified, 40.4% had stage IIIA disease, 49.9% stage II, and 8.7% stage IB. PD-L1-TC was observed in 38% of patients, EGFR mutations in 4%, and KRAS mutations in 29%. KRAS mutations were more frequent among patients with PD-L1 TC≥25% versus TC<25% (37% versus 24%). OS was not associated with PD-L1 TC≥25% versus TC<25% (stage II: adjusted HR = 1.15 [95% confidence interval: 0.66–2.01]; stage IIIA: 0.72 [0.44–1.19]). No significant association was observed with OS and PD-L1-IC ≥1% and ≥25%. EGFR and KRAS mutations were not associated with a prognostic impact. <h4>Conclusion</h4> A prognostic impact for NSCLC patients receiving adjuvant chemotherapy was not associated with PD-L1 expression, or with EGFR and KRAS mutations. |
| first_indexed | 2024-04-09T18:06:59Z |
| format | Article |
| id | doaj.art-96a68e6586004ab396c586bf8e142765 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T18:06:59Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-96a68e6586004ab396c586bf8e1427652023-04-14T05:31:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01184Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in DenmarkTapashi DalviMette NørgaardJon P. FryzekNaimisha MovvaLars PedersenHanh Pham HansenJill WalkerAnita MidhaNorah ShireAnne-Marie BoothmanJames RigasAnders MellemgaardTorben R. RasmussenStephen Hamilton-DutoitDeirdre Cronin-Fenton<h4>Introduction</h4> Programmed cell death ligand-1 (PD-L1) expression may help identify patients with non-small cell lung cancer (NSCLC) who would benefit from immunotherapy. We assessed PD-L1 expression, and epidermal growth factor receptor (EGFR) and V-Ki-Ras2 Kirsten rat sarcoma (KRAS) mutations in NSCLC patients receiving adjuvant chemotherapy. <h4>Methods</h4> Data for stage IB/II/IIIA NSCLC patients (diagnosed: 2001–2012) were retrieved from Danish population-based registries. Tumor tissue samples were tested for PD-L1 expression using VENTANA PD-L1 (SP263) Assay in tumor cells (TC) at ≥25% cutoff and immune cells (IC) at ≥1% and ≥25% cutoffs. KRAS and EGFR mutations were tested using PCR-based assays. Follow-up began 120 days after diagnosis until death/emigration/January 1, 2015, whichever came first. Using Cox proportional hazard regression, hazard ratios (HRs) were computed for overall survival (OS) for each biomarker, adjusting for age, sex, histology, comorbidities, and tissue specimen age. <h4>Results</h4> Among 391 patients identified, 40.4% had stage IIIA disease, 49.9% stage II, and 8.7% stage IB. PD-L1-TC was observed in 38% of patients, EGFR mutations in 4%, and KRAS mutations in 29%. KRAS mutations were more frequent among patients with PD-L1 TC≥25% versus TC<25% (37% versus 24%). OS was not associated with PD-L1 TC≥25% versus TC<25% (stage II: adjusted HR = 1.15 [95% confidence interval: 0.66–2.01]; stage IIIA: 0.72 [0.44–1.19]). No significant association was observed with OS and PD-L1-IC ≥1% and ≥25%. EGFR and KRAS mutations were not associated with a prognostic impact. <h4>Conclusion</h4> A prognostic impact for NSCLC patients receiving adjuvant chemotherapy was not associated with PD-L1 expression, or with EGFR and KRAS mutations.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089313/?tool=EBI |
| spellingShingle | Tapashi Dalvi Mette Nørgaard Jon P. Fryzek Naimisha Movva Lars Pedersen Hanh Pham Hansen Jill Walker Anita Midha Norah Shire Anne-Marie Boothman James Rigas Anders Mellemgaard Torben R. Rasmussen Stephen Hamilton-Dutoit Deirdre Cronin-Fenton Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark PLoS ONE |
| title | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark |
| title_full | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark |
| title_fullStr | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark |
| title_full_unstemmed | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark |
| title_short | Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark |
| title_sort | biomarker expression and survival in patients with non small cell lung cancer receiving adjuvant chemotherapy in denmark |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089313/?tool=EBI |
| work_keys_str_mv | AT tapashidalvi biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT mettenørgaard biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT jonpfryzek biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT naimishamovva biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT larspedersen biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT hanhphamhansen biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT jillwalker biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT anitamidha biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT norahshire biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT annemarieboothman biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT jamesrigas biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT andersmellemgaard biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT torbenrrasmussen biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT stephenhamiltondutoit biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark AT deirdrecroninfenton biomarkerexpressionandsurvivalinpatientswithnonsmallcelllungcancerreceivingadjuvantchemotherapyindenmark |